![]() |
市场调查报告书
商品编码
1715311
生物银行市场按类型、组件、样本类型、应用、最终用户、所有者划分——2025-2030 年全球预测Biobanks Market by Type, Component, Sample Type, Application, End User, Ownership - Global Forecast 2025-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计 2024 年生物银行市场价值为 1,154.3 亿美元,到 2025 年将成长至 1,305.6 亿美元,复合年增长率为 13.49%,到 2030 年预计将达到 2,467.2 亿美元。
主要市场统计数据 | |
---|---|
基准年2024年 | 1154.3亿美元 |
预计年份:2025年 | 1305.6亿美元 |
预测年份 2030 | 2467.2亿美元 |
复合年增长率(%) | 13.49% |
生物库已成为生物样本和相关数据的重要储存库,为研究、诊断和个人化医疗的突破提供了动力。在当今快速发展的科学环境中,这些设施是支持临床和转化研究的创新中心。在过去的十年中,技术进步以及对基因组和分子基础的深入了解使得生物库成为战略资产。这种演变推动了储存、样本分析和资料管理的改进,使科学发现更加可靠和可重复。生物库的更广泛作用不仅加速了药物发现,而且对针对患者的治疗也做出了巨大贡献。学术界、生物技术和医疗保健领域的相关人员正在加强合作,以释放新的可能性,同时应对道德、监管和营运挑战。随着市场转向整合数位平台、强大的基础设施和先进的分析工具,生物银行格局即将实现变革性成长。此次招聘既认识到历史里程碑,也认识到新兴趋势,深入说明市场动态、细分策略和策略考虑,以支持在日益激烈的竞争环境中做出有效决策。
变化中的格局:新趋势与颠覆性力量
生物银行生态系统的演变是由一种转型转变所驱动的,这种转变正在重新定义传统方法,同时为先锋方法打开大门。即时监控系统、自动化样本处理和数据分析等技术进步正在重新定义收集和管理实践。在数位革命中,平台变得越来越互通性和以用户为中心,使得从样本到分析的资料流变得快速且安全。监管改革和不断发展的道德考量也在再形成市场,推动研究机构采用更透明和严格的营运框架。同时,随着学术界、医院和商业企业重新调整策略以满足当前和未来的需求,对基因组研究和个人化医疗计划的投资增加正在进一步刺激这种转变。此外,全球都专注于发展生物银行基础设施,鼓励私部门和公部门之间的合作。这种环境的特征是快速适应和策略调整,使市场相关人员能够克服传统挑战并利用新机会。其结果不仅提高了行业标准,而且为全球生物银行行业的空前成长和协作创新铺平了道路。
洞察关键细分领域 全面多面向分析
生物银行市场的特征是复杂而又有洞察力的细分,有利于有针对性的策略和投资。首先从类型上观察该市场的结构,例如专注于疾病导向模型、基于基因组的方法、基于人群的收集以及日益相关的虚拟生物库平台的研究。此外,由于市场是透过消耗品、设备和服务进行研究的,因此按组件进行细分也发挥着重要作用。具体而言,设备细分深入到警报和监控系统、培养箱和离心机、温度控制系统等领域。在服务方面,将严格评估资料管理、样本分析、储存和处理以及转运等关键业务要素。样本类型进一步细分为血液、细胞株、核酸和组织,每种都有不同的分析和操作参数。此外,生物银行应用细分为临床诊断、个人化医疗、研究和治疗,治疗领域进一步细分为药物开发和基因编辑计画。市场区隔也根据最终用户细分(例如学术机构、生技公司、医院、製药公司等)做出投资决策。市场进一步细分为学术、商业和政府生物库。这种多方面的细分使我们能够更深入地挖掘不同的需求和创新轨迹。
The Biobanks Market was valued at USD 115.43 billion in 2024 and is projected to grow to USD 130.56 billion in 2025, with a CAGR of 13.49%, reaching USD 246.72 billion by 2030.
KEY MARKET STATISTICS | |
---|---|
Base Year [2024] | USD 115.43 billion |
Estimated Year [2025] | USD 130.56 billion |
Forecast Year [2030] | USD 246.72 billion |
CAGR (%) | 13.49% |
Biobanks have emerged as vital repositories of biological samples and associated data, fueling breakthroughs across research, diagnostics, and personalized medicine. In today's rapidly evolving scientific environment, these facilities are at the core of innovations that support clinical and translational research. Over the past decade, advancements in technology coupled with an increasing understanding of genomic and molecular underpinnings have positioned biobanks as strategic assets. This evolution has stimulated improvements in storage, sample analysis, and data management, thereby enhancing the reliability and reproducibility of scientific findings. The expansive role of biobanks not only accelerates drug discovery but also contributes significantly to patient-specific therapies. Stakeholders from academia, biotechnology, and healthcare are increasingly collaborating to unlock new possibilities while addressing ethical, regulatory, and operational challenges. As the market shifts toward integrated digital platforms, robust infrastructure, and advanced analytical tools, the biobank landscape is poised for transformative growth. Recognizing both historical milestones and emerging trends, this introduction sets the stage for a detailed exploration of market dynamics, segmentation strategies, and strategic insights that support effective decision-making in an increasingly competitive arena.
Transformative Shifts in the Landscape: Emerging Trends and Disruptive Forces
The evolution of the biobank ecosystem is driven by transformative shifts that reframe traditional methodologies while opening doors to pioneering approaches. Technological advancements, such as real-time monitoring systems, automated sample processing, and data analytics, are redefining collection and management practices. Amid a digital revolution, platforms are becoming more interoperable and user-centric, ensuring that the flow of data from sample collection to analysis is both rapid and secure. Regulatory reforms and evolving ethical considerations are also reshaping the market, prompting institutions to adopt more transparent and rigorous operational frameworks. Concurrently, increased investments in genomic research and personalized healthcare initiatives further stimulate these shifts as academia, hospitals, and commercial ventures recalibrate their strategies to align with present and future demands. In addition, the global focus on developing infrastructure for biobanking has fostered collaborations between private and public sectors. This environment is marked by swift adaptation and strategic realignment, enabling market players to overcome legacy challenges and leverage newfound opportunities. The resulting transformation is not only raising industry standards, but it is also creating pathways for unprecedented growth and collaborative innovation in biobanking worldwide.
Key Segmentation Insights: Comprehensive Analysis Across Multiple Dimensions
The biobank market is characterized by a complex yet insightful segmentation that facilitates targeted strategies and investments. The structure of this market is firstly observed through the perspective of type, with studies focusing on disease-oriented models, genomic-based approaches, population-based collections, and the increasingly relevant virtual biobank platforms. Additionally, segmentation by component plays a crucial role, as the market is examined through consumables, equipment, and services; specifically, equipment segmentation delves into areas such as alarms and monitoring systems, incubators and centrifuges, along with temperature control systems. On the services side, key operational elements such as data management, sample analysis, storage and processing, and transpost are critically evaluated. Further granularity is achieved when considering sample type segmentation, where blood derivatives, cell lines, nucleic acid, and tissues each present distinct analytical and operational parameters. The application of biobanking is also segmented into clinical diagnostics, personalized medicine, research, and therapeutics, with the therapeutics domain further dissected into drug development and gene editing ventures. Market players also align their investment decisions based on end user segments such as academic institutions, biotechnology companies, hospitals, and pharmaceutical companies. Ownership further refines the landscape into academic, commercial, and government biobanks. This multi-dimensional segmentation offers a deep dive into the diverse needs and innovation trajectories that collectively drive the market forward.
Based on Type, market is studied across Disease-Oriented, Genomic-Based, Population-Based, and Virtual.
Based on Component, market is studied across Consumables, Equipment, and Services. The Equipment is further studied across Alarms & Monitoring Systems, Incubators & Centrifuges, and Temperature Control Systems. The Services is further studied across Data Management, Sample Analysis, Storage & Processing, and Transpost.
Based on Sample Type, market is studied across Blood Derivatives, Cell Lines, Nucleic Acid, and Tissues.
Based on Application, market is studied across Clinical Diagnostics, Personalized Medicine, Research, and Therapeutics. The Therapeutics is further studied across Drug Development and Gene Editing.
Based on End User, market is studied across Academic Institutions, Biotechnology Companies, Hospitals, and Pharmaceutical Companies.
Based on Ownership, market is studied across Academic Biobanks, Commercial Biobanks, and Government Biobanks.
Key Regional Insights: Global Diffusion and Local Nuances
Examining the biobank landscape on a global scale unravels significant regional trends and market drivers. In the Americas, a combination of advanced infrastructure, robust funding initiatives, and a well-established network of research institutions creates a fertile ground for biobanking innovation. Both government and private sectors contribute extensively to research support and infrastructure development across these regions, making it a hotspot for cutting-edge developments. In contrast, the Europe, Middle East, and Africa regions exhibit a unique blend of regulatory dynamics and a commitment to traditional as well as pioneering research methodologies. These regions place a strong emphasis on ethical standards and data transparency while steadily advancing their technological capabilities. Meanwhile, the Asia-Pacific market reflects rapid economic growth, a surge in biotechnological investments, and an expanding research framework that is quickly adapting to the demands of modern biobanking. The interplay of local policies, infrastructural investments, and growing public-private partnerships in these regions creates diverse opportunities and challenges, ultimately contributing to the global diffusion and evolution of biobank practices.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Key Companies Insights: Market Leaders Shaping the Competitive Landscape
A number of prominent companies are making substantial contributions to driving growth and innovation within the biobank industry. Leading organizations like Acorn Biolabs, Inc. and AMS Biotechnology (Europe) Limited have carved out niches by providing advanced solutions tailored to specific market needs. Companies such as Artizan Biosciences, Inc. and ASKION GmbH have set exemplary high standards through their commitment to precision and technological advancement. Industry titans including Avantor, Inc. and Bay Biosciences LLC, alongside established brands such as Beckman Coulter, Inc. by Danaher Corporation and Becton, Dickinson and Company, are continuously enhancing operational efficiencies and pushing the boundaries of research solutions. Enterprises like BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., and BocaBio demonstrate notable strength by integrating innovative technologies into their service offerings. Furthermore, diversified multinational corporations such as Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, and Cureline, Inc. further fortify market competitiveness. Other influential players, including Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited, continue to drive innovative research and deploy forward-thinking solutions, each leaving a significant imprint on this rapidly maturing market.
The report delves into recent significant developments in the Biobanks Market, highlighting leading vendors and their innovative profiles. These include Acorn Biolabs, Inc., AMS Biotechnology (Europe) Limited, Artizan Biosciences, Inc., ASKION GmbH, Avantor, Inc., Bay Biosciences LLC, Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited. Actionable Recommendations for Industry Leaders: Strategic Steps for Future Growth
Industry leaders are advised to adopt comprehensive strategies that address both current challenges and future opportunities in the rapidly evolving biobank market. A primary recommendation is to invest in state-of-the-art technological infrastructure that supports automated processes and real-time monitoring. Embracing digitalization not only enhances operational efficiency but also ensures data integrity and security across the supply chain. Leaders should also consider fostering partnerships with key stakeholders, including academic institutions, biotechnology firms, and healthcare providers, to facilitate knowledge exchange and joint ventures. Building resilient, compliant frameworks that align with stringent regulatory standards is essential; hence, legal and procedural audits should be conducted routinely to uphold transparency and accountability. It is imperative to tailor innovations based on market segmentation insights: customizing solutions to address the varied demands based on type, component, sample type, application, end user, and ownership segments. Furthermore, understanding regional dynamics and adapting to local market conditions will enable more informed decision-making, particularly in diverse territories such as the Americas, Europe, Middle East and Africa, and Asia-Pacific. These strategic recommendations are geared toward positioning companies to capture growth opportunities while mitigating risks in an environment characterized by relentless innovation and changing market paradigms.
Conclusion: Embracing Change and Navigating Future Opportunities
In conclusion, the analysis of the biobank market reveals a vibrant and evolving industry defined by technological innovation, strategic segmentation, and a global spread of opportunities. The comprehensive review provided throughout this document underscores that biobanks are no longer solely repositories for biological samples; they are dynamic entities central to advancements in personalized medicine, clinical diagnostics, and advanced research. With transformative shifts reshaping the market and key players driving technological and operational progress, stakeholders can leverage these insights to navigate the competitive landscape. As emerging trends continue to accelerate, the collective focus on integrating robust infrastructural investments, adhering to stringent regulatory standards, and fostering strategic collaborations will determine the success of industry participants. This evolving market offers both substantial challenges and compelling opportunities, making it imperative for organizations to remain agile and informed as they embark on new initiatives and expansion strategies.